Apheresis (Therapeutic Pheresis) — NCD 82 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 82 governing apheresis (therapeutic pheresis) coverage, with an effective date of March 7, 2026. Here's what billing teams need to know.

CMS apheresis coverage policy under NCD 82 in the Medicare system covers a defined list of 13 indications — but only when performed in a qualifying setting with direct physician oversight. This policy does not list specific CPT or HCPCS codes, which means your documentation and coding discipline carry most of the weight. If your facility bills apheresis for Medicare patients, review your indication documentation and site-of-service requirements now, before March 7, 2026.

Quick-Reference Table

CMS Apheresis Coverage Criteria and Medical Necessity Requirements 2026

NCD 82 is the National Coverage Determination governing Medicare coverage of apheresis — also called pheresis or therapeutic pheresis. The procedure removes specific blood components (plasma, leukocytes, platelets, or cells) from whole blood, then returns the remainder to the patient. CMS defines covered apheresis strictly as an autologous procedure. Blood is drawn, processed, and returned to the same patient in a single continuous procedure.

That definition matters for billing. If your facility performs a procedure where blood is donated preoperatively and transfused later, that falls outside this coverage policy. Don't confuse the two in your documentation.

Medical necessity under NCD 82 is indication-specific. CMS covers apheresis for 13 defined conditions — and nothing else. There is no blanket coverage for therapeutic pheresis. Every claim needs to trace back to one of those 13 indications or you're looking at a claim denial.

Several indications carry additional medical necessity criteria beyond the diagnosis itself. For example, plasmapheresis for thrombotic thrombocytopenic purpura (TTP) and life-threatening rheumatoid vasculitis must both be documented as "last resort" treatment. Chronic relapsing polyneuropathy requires documentation that the patient has severe or life-threatening symptoms and has failed conventional therapy. Scleroderma and polymyositis coverage requires the patient to be unresponsive to conventional therapy. Systemic lupus erythematosus (SLE) requires conventional therapy to have failed and clinical deterioration to be ongoing.

These aren't just clinical notes — they're billing requirements. If the medical record doesn't document treatment failure or last-resort status explicitly, your claim is exposed.

This policy does not mention prior authorization requirements for apheresis. However, absence of a prior authorization requirement in an NCD doesn't mean your MAC won't impose one at the local level. Check with your Medicare Administrative Contractor before submitting apheresis claims, especially for the indications with more complex criteria. If your billing team isn't sure how local coverage determinations from your MAC interact with NCD 82, loop in your compliance officer before the effective date.

Reimbursement for apheresis under Medicare flows through the applicable benefit category — physician services, outpatient hospital services incident to a physician's service, or incident-to services. Your setting determines which category applies and how reimbursement is calculated.

CMS Apheresis Exclusions and Non-Covered Indications

NCD 82 doesn't contain an explicit "not covered" list in the way some NCDs do. But the structure of the policy creates clear exclusions by omission. If a condition isn't on the 13-indication list, it's not covered. Period.

The policy also excludes any apheresis that isn't autologous. Blood donation procedures — where a patient donates blood before surgery and receives it back later — are not covered under this NCD.

The "last resort" and "conventional therapy failure" language on several indications creates a soft exclusion. If a patient hasn't yet tried conventional therapy, or if the record doesn't document that conventional therapy failed, apheresis for those conditions doesn't meet medical necessity under this policy. Submitting without that documentation is a denial waiting to happen.

Coverage Indications at a Glance

CMS Apheresis Billing Guidelines and Action Items 2026

1. Audit your active apheresis patient roster against the 13 covered indications before March 7, 2026.

Pull every active or pending apheresis case billed to Medicare. Match each case to one of the 13 NCD 82 indications. If a case doesn't map cleanly, escalate it to your clinical documentation team before the effective date.

2. Confirm "last resort" and "treatment failure" language appears explicitly in the medical record.

For TTP, rheumatoid vasculitis, polyneuropathy, scleroderma, polymyositis, and SLE, the medical record must document what conventional therapies were tried, how long they were tried, and why they failed or were inadequate. "Last resort" isn't a checkbox — it's a narrative. Make sure your physicians know exactly what the documentation standard is.

3. Verify site-of-service documentation meets NCD 82 requirements.

This policy covers apheresis in hospital settings (inpatient or outpatient) and in non-hospital settings like physician-directed clinics — but only under three conditions. A physician must be present during all patient care hours. Each patient must be under a physician's care. All non-physician services must be under direct, personal physician supervision. Build a site-of-service attestation into your billing workflow for every apheresis encounter.

4. Check with your MAC for any local coverage determination that layers on top of NCD 82.

NCD 82 sets the national floor. Your Medicare Administrative Contractor may have an LCD with tighter criteria, prior authorization requirements, or additional documentation standards. Don't assume the NCD is the whole picture. Contact your MAC or check their LCD database before submitting claims under the modified policy.

5. Review your charge capture process for the absence of specific codes in this policy.

NCD 82 does not list specific CPT or HCPCS codes. That's not unusual for an NCD, but it means your apheresis billing depends entirely on correct diagnosis coding and clinical documentation — not just procedure code matching. Talk to your coding team about how they're capturing the correct ICD-10-CM diagnosis codes that correspond to each covered indication. A claim denial here is almost always a documentation problem, not a code problem.

6. If your facility bills both inpatient and outpatient apheresis, confirm the correct benefit category is being used.

NCD 82 covers apheresis under three benefit categories: incident to a physician's professional service, outpatient hospital services incident to a physician's service, and physicians' services. Which category applies depends on your setting and how the service is structured. A mismatch between setting and benefit category is a common source of improper billing. If you're not certain which applies to your facility, talk to your compliance officer or billing consultant before the effective date.

CPT, HCPCS, and ICD-10 Codes for Apheresis Under NCD 82

A Note on Code Availability

NCD 82 as modified does not list specific CPT, HCPCS, or ICD-10 codes in the policy document. This is common for older NCDs that were written before standardized code tables became part of the NCD format. The apheresis billing guidelines and action items above apply regardless, because coverage is determined by indication and documentation — not by a specific code list.

Your coding team should map the 13 covered indications to the appropriate ICD-10-CM diagnosis codes and use the procedure codes your facility currently bills for apheresis services. If you don't have a code crosswalk in place for these indications, build one now. Work with your MAC or a certified coding consultant to confirm the right procedure codes for each apheresis type (plasmapheresis, leukapheresis, plasma exchange, plasma perfusion).

Do not rely on any CPT or HCPCS codes not sourced directly from NCD 82 or your MAC's LCD. Fabricated code tables are a liability — and they're common in generic billing guidance online.